Zannettino AC - Search Results

1

Imatinib as a potential antiresorptive therapy for bone disease.

Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B, Zannettino AC. Dewar AL, et al. Among authors: zannettino ac. Blood. 2006 Jun 1;107(11):4334-7. doi: 10.1182/blood-2005-09-3568. Epub 2006 Jan 31. Blood. 2006. PMID: 16449525 Free article.

2

The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesis.

Zannettino AC, Bühring HJ, Niutta S, Watt SM, Benton MA, Simmons PJ. Zannettino AC, et al. Blood. 1998 Oct 15;92(8):2613-28. Blood. 1998. PMID: 9763543 Free article.

3

Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.

Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino AC, Hay S, Findlay DM. Atkins GJ, et al. Among authors: zannettino ac. Bone. 2001 Apr;28(4):370-7. doi: 10.1016/s8756-3282(01)00404-5. Bone. 2001. PMID: 11336917

4

RANKL expression is related to the differentiation state of human osteoblasts.

Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, Harrison K, Findlay DM, Zannettino AC. Atkins GJ, et al. Among authors: zannettino ac. J Bone Miner Res. 2003 Jun;18(6):1088-98. doi: 10.1359/jbmr.2003.18.6.1088. J Bone Miner Res. 2003. PMID: 12817763 Free article.

5

Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.

Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino AC. Farrugia AN, et al. Among authors: zannettino ac. Cancer Res. 2003 Sep 1;63(17):5438-45. Cancer Res. 2003. PMID: 14500379

6

The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro.

Pan B, To LB, Farrugia AN, Findlay DM, Green J, Gronthos S, Evdokiou A, Lynch K, Atkins GJ, Zannettino AC. Pan B, et al. Among authors: zannettino ac. Bone. 2004 Jan;34(1):112-23. doi: 10.1016/j.bone.2003.08.013. Bone. 2004. PMID: 14751568

7

The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).

Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC. Pan B, et al. Among authors: zannettino ac. J Bone Miner Res. 2004 Jan;19(1):147-54. doi: 10.1359/jbmr.2004.19.1.147. J Bone Miner Res. 2004. PMID: 14753746 Free article.

8

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, Lyons AB. Dewar AL, et al. Among authors: zannettino ac. Blood. 2005 Apr 15;105(8):3127-32. doi: 10.1182/blood-2004-10-3967. Epub 2005 Jan 6. Blood. 2005. PMID: 15637141 Free article.

9

Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells.

Kortesidis A, Zannettino A, Isenmann S, Shi S, Lapidot T, Gronthos S. Kortesidis A, et al. Blood. 2005 May 15;105(10):3793-801. doi: 10.1182/blood-2004-11-4349. Epub 2005 Jan 27. Blood. 2005. PMID: 15677562 Free article.

10

Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.

Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N, Gronthos S. Zannettino AC, et al. Cancer Res. 2005 Mar 1;65(5):1700-9. doi: 10.1158/0008-5472.CAN-04-1687. Cancer Res. 2005. PMID: 15753365

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

221 results

Search Page

Filters